Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-22-007439
Filing Date
2022-05-05
Accepted
2022-05-05 16:51:30
Documents
47
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q nxtc-20220331x10q.htm   iXBRL 10-Q 891500
2 EX-31.1 nxtc-20220331xex31d1.htm EX-31.1 12898
3 EX-31.2 nxtc-20220331xex31d2.htm EX-31.2 12679
4 EX-32.1 nxtc-20220331xex32d1.htm EX-32.1 12246
  Complete submission text file 0001558370-22-007439.txt   3900637

Data Files

Seq Description Document Type Size
5 EX-101.SCH nxtc-20220331.xsd EX-101.SCH 22266
6 EX-101.CAL nxtc-20220331_cal.xml EX-101.CAL 33933
7 EX-101.DEF nxtc-20220331_def.xml EX-101.DEF 85657
8 EX-101.LAB nxtc-20220331_lab.xml EX-101.LAB 261955
9 EX-101.PRE nxtc-20220331_pre.xml EX-101.PRE 174819
41 EXTRACTED XBRL INSTANCE DOCUMENT nxtc-20220331x10q_htm.xml XML 674373
Mailing Address 9000 VIRGINIA MANOR ROAD, SUITE 200 BELTSVILLE MD 20705
Business Address 9000 VIRGINIA MANOR ROAD, SUITE 200 BELTSVILLE MD 20705 240-399-4900
NextCure, Inc. (Filer) CIK: 0001661059 (see all company filings)

EIN.: 475231247 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38905 | Film No.: 22897302
SIC: 2834 Pharmaceutical Preparations